Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
86 hedge funds and large institutions have $462M invested in Rubius Therapeutics, Inc in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 13 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
38% more capital invested
Capital invested by funds: $335M → $462M (+$127M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more funds holding
Funds holding: 76 → 86 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.22M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.71M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.2M |
| 4 |
BlackRock
New York
|
+$1.91M |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$3.81M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.42M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$630K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$572K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$330K |
RUBY Hedge Fund Activity: Q2 2020 in Review
86 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2020, worth a combined $462M — up 38% from $335M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RUBY positions and 13 closed out — a net gain of 10 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $5.22M. The largest seller was Capital World Investors, cutting an estimated $3.81M.
- 86 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2020, up from 76 in Q1 2020.
- Funds reported $462M of Rubius Therapeutics, Inc stock for Q2 2020, up 38% quarter-over-quarter.
- 23 funds opened new Rubius Therapeutics, Inc positions in Q2 2020 and 13 closed out, a net change of +10 holders.
- The largest Rubius Therapeutics, Inc buyer in Q2 2020 was JP Morgan Chase, an estimated $5.22M added.
- The largest Rubius Therapeutics, Inc seller in Q2 2020 was Capital World Investors, an estimated $3.81M sold.
Based on aggregated 13F filings for Q2 2020.